NuSight Granted U.S. Patent Covering the NuLids System for Treating Dry Eye Disease

More Images
RANCHO SANTA FE, Calif.—NuSight Medical announced that the U.S. Patent Office has issued a patent for its NuLids System for the treatment of dry eye/ocular surface disease, blepharitis and related conditions. “The patent protects our entire NuLids system – the device and methods for its use, the disposable soft-tips, and product safety features” said Robert Foster, CEO of NuSight Medical. All 29 claims in U.S. Patent No. 10,314,763 were approved providing key declarations that involve stimulating the meibomian glands to effectively treat dry eye.

The patent’s abstract refers to “ improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands...”

NuSight Medical has additional patent applications pending.